ASCO GU 2023 Prostate Cancer - Results from #80

Viewing 81-95 of 95 articles

ASCO GU 2023: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual Patient Data Meta-Analysis from the MARCAP Consortium

ASCO GU 2023: Association of Intermittent vs Continuous Androgen Deprivation Therapy with Cardiovascular Disease and Endocrine/metabolic Disorders in Patients with Metastatic Prostate Cancer

ASCO GU 2023: Influence of Molecular Imaging on Patient Selection for Treatment Intensification Prior to Salvage Radiation Therapy for Prostate Cancer: A Post Hoc Analysis of the PROPS Trial

ASCO GU 2023: Best of the Journals: Prostate Cancer - Medical Oncology

ASCO GU 2023: Darolutamide plus ADT Versus ADT in Metastatic Hormone-Sensitive Prostate Cancer: Open-Label Single-Arm Study with an External Control Arm (ARASEC)

ASCO GU 2023: Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults with Metastatic Castration-Sensitive Prostate Cancer

ASCO GU 2023: Time Interval Between Radium‑223 Therapy and Lutetium-177–prostate-Specific Membrane Antigen (177Lu-PSMA) Treatment and Outcomes in the RALU Study

ASCO GU 2023: Initial Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

ASCO GU 2023: Activity of Lutetium-177 PSMA (Lu-PSMA) and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Cabazitaxel: The PACAP Study

ASCO GU 2023: Evaluation of a Novel Transcriptomic Tumor Signature (PROSTest) as Response Biomarker for 177Lu-PSMA Therapy in Advanced Prostate Cancer

ASCO GU 2023: Best of the Journals: Prostate Cancer - Urologic Oncology

ASCO GU 2023: Impact of Run-in Treatment with Abiraterone Acetate and Prednisone in the MAGNITUDE Study of Niraparib and AAP in Patients with mCRPC and Homologous Recombination Repair Gene Alterations

ASCO GU 2023: Efficacy of Systemic Therapy Following [177Lu] Lu-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2023: Best of the Journals: Prostate Cancer - Pathology

ASCO GU 2023: Best of the Journals: Prostate Cancer - Radiation Oncology

1
2
3
4
5